Creative Biolabs has expanded its specialized antibody portfolio targeting structural and envelope proteins from HIV-1, HIV-2, and HTLV-1, the company announced. The expansion addresses a critical need in human retrovirus research, where access to well-characterized reagents that distinguish specific viral proteins is essential for advancing virology, immunology, vaccine development, and diagnostic assay development.
At the forefront of HIV-1 research is the viral envelope. The gp140 protein, an uncleaved ectodomain of the HIV-1 envelope glycoprotein, serves as a primary target for broadly neutralizing antibodies and vaccine design. Creative Biolabs now offers an anti-gp140 HIV-1 antibody for research applications involving HIV-1 envelope biology, antigen recognition, and related assay development. This reagent is expected to support studies aimed at understanding how the virus enters cells and how the immune system recognizes it, which is critical for vaccine strategies.
While HIV-1 accounts for the majority of global infections, HIV-2 presents unique clinical challenges due to its distinct genetic makeup and different disease progression rates. Because gp36 is an HIV-2 envelope-associated antigen, antibodies targeting gp36 can be useful research tools for studying antigen recognition, cross-reactivity, and the development and evaluation of HIV-2-focused assay concepts. The availability of such reagents may improve the ability to differentiate between HIV-1 and HIV-2 infections in research settings and to probe the nuances of HIV-2 biology.
Beyond HIV, the human T-cell lymphotropic virus type 1 (HTLV-1) represents another significant retroviral threat. HTLV-1 is the causative agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy. HTLV-1 gag p19 is a viral core protein commonly investigated in studies of HTLV-1 biology, viral protein expression, and immune recognition. Creative Biolabs' anti-HTLV-1 gag p19 antibody is intended for research applications such as Western blot, ELISA, and immunohistochemistry, supporting research into HTLV-1 pathogenesis and related virology questions. This antibody could accelerate investigations into how HTLV-1 establishes persistence and causes disease.
“Retrovirus research often depends on reagents that distinguish specific viral proteins and support different experimental formats,” said a senior scientist at Creative Biolabs. “By expanding antibody coverage across HIV-1, HIV-2, and HTLV-1 targets, we aim to give researchers additional options for studying viral proteins, antigen recognition, and assay development.”
The expanded portfolio is designed for research applications involving HIV-1, HIV-2, and HTLV-1 proteins, and the company also provides custom antibody development services for virology and infectious disease research. For more information about the complete range of retrovirus-targeted antibodies and custom services, visit https://www.antibody-creativebiolabs.com/. The company emphasizes that its products are for research use only and are not for use in diagnostic or therapeutic procedures.
This expansion matters because human retroviruses continue to pose global health challenges, and the development of effective vaccines, therapies, and diagnostics hinges on robust research tools. By offering antibodies that target key viral proteins, Creative Biolabs is equipping scientists with the means to dissect viral mechanisms, evaluate immune responses, and refine assay concepts. The addition of these reagents may help accelerate discoveries in retrovirus research, ultimately contributing to better strategies for combating HIV and HTLV-1 infections worldwide.
